Zurück zu den Rankings

The Ensign Group, Inc. (ENSG)

Fair bewertet
HealthcareMedical Care FacilitiesUnited States

Fundamental

68

Kurs

$172.00

Marktkapitalisierung

$10.02B

Teil 1 · Was das Unternehmen wert ist

Übersicht

The Ensign Group is a US healthcare holding company, founded in 1999 and based in San Juan Capistrano, California, whose independent operating subsidiaries run skilled nursing facilities, senior living communities and related ancillary services. At December 31, 2025 the group operated 373 healthcare and senior living operations across 17 states, including 357 skilled nursing operations with roughly 37,900 beds and about 3,400 senior living units. A separate captive real-estate subsidiary, Standard Bearer, owned about 152 properties, most of them leased to Ensign-affiliated operators and the rest to third parties. Ensign grows mainly by acquiring or leasing underperforming facilities and turning them around under local management; each facility is run as a stand-alone business with its own leadership, rather than from a central corporate office. Consolidated revenue for fiscal 2025 was $5.06 billion and net income $344.3 million.

Wie das Geld verdient wird

Ensign is paid per patient per day of care. Revenue comes from Medicaid (the largest source), Medicare, managed-care plans and private payors, at rates that are largely set by federal and state programs rather than negotiated freely. Profitability therefore depends on three levers the company manages facility by facility: occupancy, payor mix (the share of higher-reimbursement 'skilled' days, mainly Medicare and managed care) and labour cost per day. A second, much smaller stream is rent: the Standard Bearer subsidiary collects lease payments on the properties it owns, though most of that rent is paid by Ensign's own operators and is eliminated in consolidation, so only the third-party rent reaches consolidated revenue.

Umsatz nach Segment

Skilled Services93.1%

Operation of skilled nursing facilities and rehabilitation therapy services: post-acute nursing, rehabilitation and long-term custodial care for patients, mostly elderly, paid for by Medicaid, Medicare, managed-care plans and private payors. It generated $4.84 billion of segment revenue in fiscal 2025.

All Other4.5%

Everything the company does not treat as a reportable segment: stand-alone senior living communities, mobile diagnostics, medical transportation, other real estate and the Service Center. Revenue was $232.8 million in fiscal 2025; individually none of these activities is large enough to be a reportable segment.

Standard Bearer2.4%

The group's captive real-estate arm, which owns the buildings and leases them to operators — mostly to Ensign-affiliated operations, the rest to third parties. It reported $126.9 million of rental revenue in fiscal 2025, the large majority of which is intercompany rent eliminated on consolidation.

Wettbewerbsvorteil

Kein erkennbarer Vorteil · Keiner

Skilled nursing is a local, licence-based business in which prices are set by government programs, not by the provider, so scale buys little pricing power. What Ensign describes as its advantage is an operating method — decentralised local leadership, a cluster of facilities in each market, and a track record of buying troubled facilities and lifting their occupancy, payor mix and quality ratings. That is a management skill rather than a structural barrier: it can be copied, and it has to be re-earned with every acquisition. Licensure and, in some states, certificate-of-need rules do limit how quickly new beds appear, but they protect incumbents generally rather than Ensign specifically.

Was die Nachfrage antreibt

Defensiv

Demand is driven by medical need and demographics, not by the economic cycle: people enter a skilled nursing facility after a hospital stay or because they can no longer be cared for at home, and that does not stop in a recession. The real swing factors are policy and labour — federal and state reimbursement decisions, and whether there are enough staff to fill available beds — plus one-off shocks such as the pandemic, which pushed occupancy sharply down before it recovered. Same-facility occupancy averaged 82.9% in fiscal 2025.

Wichtigste Risiken

  • Dependence on Medicare and Medicaid rules and rates — The company discloses that reductions in reimbursement rates, changes to payment models, spending requirements, data reporting and quality measurement under Medicare and Medicaid could materially hurt revenue and results. Government programs are the dominant payor, annual inflation adjustments may not continue or may not cover actual cost increases, and several states require a set portion of Medicaid revenue to be spent directly on care.
  • Geographic concentration in a few states — The filing flags that a majority of revenue comes from operations in a small number of states — notably Arizona, California and Texas — so an economic downturn, a state budget or regulatory change, or a natural event in those areas would hit results disproportionately. State Medicaid budgets move independently of one another, and the company notes very different conditions across its states.
  • Availability and cost of clinical staff — Ensign discloses that it competes for nurses, therapists and facility leaders in a tight labour market, and that wage pressure, turnover and minimum-staffing requirements can raise costs faster than reimbursement rises. Since rates are largely administered, higher labour cost per patient day cannot simply be passed on to the payor.
  • Professional liability and malpractice litigation — The company discloses exposure to general and professional liability claims typical of long-term care, with significant self-insured retentions and claims-made coverage limits, and notes that California has raised the cap on non-economic damages in medical malpractice suits. Adverse claims experience can raise both settlement costs and future insurance premiums.
  • Execution risk in acquisitions — Growth depends on finding, acquiring and integrating operations, often troubled ones. The filing warns that suitable targets may not be available, that acquired facilities may not reach expected performance, that integration stretches management capacity, and that state approval processes — California's OHCA review is cited — can delay or block transactions.
  • Licensure, surveys and quality ratings — Facilities must keep state licences and Medicare/Medicaid certification and are subject to recurring surveys; sanctions can include fines, admission bans or loss of certification at a given facility. The company also notes that the CMS Five-Star rating system and changing quality measures affect both referrals and reimbursement.

Kundenkonzentration

Die größten Kunden machen 69.5 % des Umsatzes aus

There is no large commercial customer: patients are individuals, but the money comes from a handful of payors. In fiscal 2025 Medicaid and Medicare together accounted for 69.5% of service revenue, with managed-care plans and private payors making up the rest. The concentration that matters is therefore political and administrative — a single federal or state decision moves a large slice of revenue at once — rather than the loss of a contract.

Die Argumente dafür

Buyers argue that the demographics are unarguable — the population needing post-acute and long-term care keeps growing while few new beds are built — and that Ensign has a repeatable machine for turning acquired facilities around: consolidated revenue grew 18.7% in fiscal 2025 to $5.06 billion, with occupancy at same-facility level averaging 82.9% and still rising. They point to the decentralised model, which lets each facility leader respond to a local market, to a long runway of small, family-owned operators available to acquire, and to Standard Bearer's owned real estate as both a source of rent and collateral for further deals.

Die Argumente dagegen

Sellers fear that almost 70% of revenue depends on government programs whose rates are decided elsewhere: a federal payment-model change or a state Medicaid squeeze can compress margins with no commercial remedy, and the company itself lists this first among its risks. They also point to labour — wage inflation and staffing requirements raise cost per patient day faster than administered rates rise — to the litigation exposure inherent in long-term care, with large self-insured retentions and a higher damages cap in California, and to the fact that growth leans on a steady flow of acquisitions, each of which has to be integrated and turned around before it earns anything.

Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users

Direct competitors

Who this company fights with for the same customers

Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users

PACS Group, Inc.PACS

PACS runs the second-largest US skilled nursing platform, over 300 post-acute facilities across many of the same Western and Midwestern states, competing for the same Medicare and Medicaid post-acute patients and the same hospital discharge referrals as Ensign.

Life Care Centers of America, Inc.Not tracked

Privately held Tennessee operator of roughly 200 skilled nursing centers and 40 assisted living communities, the third-largest US nursing home chain by patient revenue and a direct rival for post-acute admissions in overlapping states.

National HealthCare CorporationNHC

The other listed pure-play US skilled nursing operator, with about 80 nursing centers plus assisted living, home care and hospice, serving the same elderly post-acute and long-stay residents in the Southeast.

Genesis HealthCare, Inc.Not tracked

Delisted since 2021 and in Chapter 11 since July 2025, Genesis still operates roughly 175-200 skilled nursing and senior living centers in 18 states, bidding for the same post-acute patients and the same facility acquisitions.

Marquis Health Consulting Services (Marquis Health Services)Not tracked

Privately held regional skilled nursing group among the five largest US operators by patient revenue, growing through the same strategy of acquiring and turning around underperforming nursing facilities.

Bilanz & Liquidität

Umsatz

$5.46B

Letzte 12 Monate (bis 30.6.2026)

Nettogewinn

$379M

Letzte 12 Monate (bis 30.6.2026)

Freier Cashflow

-

Gesamtes Eigenkapital

$2.23B

Gesamtverbindlichkeiten

$3.23B

Current Ratio

1.21

Zinsdeckungsgrad

59.99

Schulden/EBITDA

4.25

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Allgemeiner FallFair bewertet

Innerer Wert

$154.72

Aktueller Kurs

$172.00

Sicherheitsmarge

-11.2%

Innerer-Wert-Spanne

$100.57 - $208.88

Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.

Bewertungsmethoden

Kursziel der Analysten:$220.00
Diskontierter Cashflow (DCF):$93.57
Gewinnmultiplikator (P/E):$137.70
Graham-Wachstumsformel:$207.27
Ertragskraftwert (EPV):$75.64
Gerechtfertigtes P/B:$114.51
Dividendendiskontierung (Gordon):$6.17
P/FFO, Funds from Operations:$123.07
Gewinn im Zyklusmittel:$155.85
Umsatzmultiplikator:$363.42
Analystenkonsens:Starker Kauf (10B / 2H / 0S)
Letzte Gewinnüberraschung:+2.16%

Bewertungskennzahlen

P/E-Verhältnis

26.96

ROE

15.4%

P/B-Verhältnis

4.11

P/FCF

-

Bruttomarge

20.3%

ROIC

7.6%

Rentabilitäts-Radar

Wertschöpfung (Wettbewerbsvorteil)

ROIC

7.6%

WACC

6.8%

ROIC − WACC

+0.8 pp

Der ROIC liegt etwa auf Höhe der Kapitalkosten: Das Unternehmen deckt gerade eben seine Kapitalkosten.

Fundamentalanalyse-Kriterien

Bestanden (18)

  • EPS shows upward trend
  • EPS CAGR 8.64%
  • Price CAGR 23.79%
  • ROIC 7.6%
  • Debt/Equity ratio
  • Operating Margin 8.6%
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 16.5%
  • Revenue Growth 5Y 16.1%
  • Analyst Consensus 83% Buy
  • PEG Ratio 1.93
  • Earnings Quality (OCF/NI) 1.61
  • Share Dilution 1.2%
  • Piotroski F-Score 5/9

Nicht bestanden (6)

  • Gross Margin 20.3%
  • P/B Ratio 4.11
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Earnings Surprise avg 0.7%
  • Net Margin Trend 6.9% vs 7.0%

Nicht verfügbar (4)

  • P/FCF NaN
  • Dividend Payout NaN%
  • Positive Free Cash Flow
  • CapEx intensity

Piotroski F-Score

5/9

Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit

score
criteria

Gewinnqualität

1.61

Hohe Qualität: Gewinne durch Cashflow gedeckt

Aktienverwässerung

1.2%

Aktienanzahl ist stabil

Institutionelle Beteiligungen

Unternehmensführung

Führungsteam

NamePositionAlter
Mr. Barry R. PortCEO & Chairman of the Board51
Mr. Spencer W. BurtonPresident & COO46
Ms. Suzanne D. Snapper CPACFO, Executive VP & Director51
Mr. Chad A. Keetch J.D.Chief Investment Officer, Executive VP & Secretary47
Ms. Beverly B. WittekindExecutive VP & General Counsel60
Kevin ReesePresident of Keystone Healthcare Inc-

Prüfungsrisiko

7

Vorstandsrisiko

5

Vergütungsrisiko

7

Aktionärsrechterisiko

2

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Dokumente

  • Jahresbericht (10-K)

    Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.

    Eingereicht am 2026-02-04

    Dokument ansehen
  • Quartalsbericht (10-Q)

    Ein Update zur finanziellen Entwicklung der letzten drei Monate.

    Eingereicht am 2026-07-27

    Dokument ansehen
  • Ad-hoc-Meldung (8-K)

    Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.

    Eingereicht am 2026-08-25

    Dokument ansehen

via SEC EDGAR

Ertragshistorie

via SEC EDGAR

Latest News

Recent headlines for ENSG, sourced from Markets Gazette.

No recent news for ENSG.